Oric Pharmaceuticals presents data from Phase 1b trial of enozertinib

ORIC Pharmaceuticals (ORIC) announced data from a Phase 1b trial of enozertinib, ORC-114, at the ESMO Asia Congress 2025. Data in treatment-naive and in previously treated NSCLC patients with EGFR exon 20 mutations were presented at an oral session. Key highlights: Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR , including in patients with active brain metastases; 45% ORR in 2L patients exceeds competitor benchmarks; Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate; Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial